These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21057566)

  • 41. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
    Hurle R; Losa A; Manzetti A; Lembo A
    Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.
    Pansadoro V; Emiliozzi P; de Paula F; Scarpone P; Pansadoro A; Sternberg CN
    Urology; 2002 Feb; 59(2):227-31. PubMed ID: 11834391
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?
    Pagano F; Bassi P; Milani C; Meneghini A; Maruzzi D; Garbeglio A
    J Urol; 1991 Jul; 146(1):32-5. PubMed ID: 2056600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
    Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
    Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.
    Sood R; Sharma H; Sharma B; Parekh S; Pujari P; Shewale S
    Urol Oncol; 2020 May; 38(5):433-439. PubMed ID: 32037199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
    Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
    Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.
    Zhang GK; Uke ET; Sharer WC; Borkon WD; Bernstein SM
    J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.
    Leblanc B; Duclos AJ; Bénard F; Valiquette L; Paquin JM; Lapointe S; Mauffette F; Pharand D; Faucher R; Drouin G; Perreault JP
    Can J Urol; 2000 Feb; 7(1):944-8. PubMed ID: 11121250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer.
    Mack D; Frick J
    Urology; 1995 Jun; 45(6):958-61. PubMed ID: 7771030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
    Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.
    Baba M; Kageyama S; Yoshida T; Fujiwara R; Kim CJ; Takimoto K; Nagasawa M; Soga H; Nagatani Y; Nishikawa Z; Kawauchi A
    Int J Clin Oncol; 2018 Oct; 23(5):951-956. PubMed ID: 29761307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Intravesical therapy of non-muscle invasive bladder tumors].
    Vom Dorp F; Tschirdewahn S; Lümmen G
    Urologe A; 2012 Feb; 51(2):257-64. PubMed ID: 22331075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
    Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
    BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moreau Strain Bacillus Calmette-Guérin Low Versus Standard Dose in the Treatment of High-Grade T1 Bladder Cancer: A Retrospective Observational Cohort Study.
    Carneiro BDB; Sanches BCF; Andrade DL; Voris BRI; Reis LO
    Clin Genitourin Cancer; 2019 Aug; 17(4):e779-e783. PubMed ID: 31160192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
    Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ; van der MEIJDEN AP; Lamm DL
    J Urol; 2002 Nov; 168(5):1964-70. PubMed ID: 12394686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.